Diligence memo · auto-generated · as of July 3, 2026
Genebiology, Inc.
Genebiology, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Genebiology, Inc. operates in Pharmaceuticals, based in RALEIGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Genebiology, Inc. has raised $400K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $400K on 2015-08-07.
Most recent recorded round closed around 2015-08-07.
Valuation (modeled)modeled
Provath models Genebiology, Inc. at approximately $19M (range $224K–$215M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.67× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 10.9 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 10% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 27% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.